SGI-7079

SGI-7079 is a small molecule inhibitor of the Axl receptor tyrosine kinase, a member of the TAM (Tyro3, Axl, Mer) family. Originally developed by SuperGen (now Astex Pharmaceuticals) for the treatment of solid tumors and hematological malignancies, SGI-7079 has more recently been investigated for its anti-inflammatory properties. Specifically, research conducted by institutions such as Suining Central Hospital has focused on its ability to inhibit the NLRP3 inflammasome-related inflammatory response. In models of gout, SGI-7079 has demonstrated the potential to reduce the production of interleukin-1 beta (IL-1β) and other inflammatory mediators triggered by monosodium urate (MSU) crystals. By blocking Axl-mediated signaling, the compound attenuates the activation of the NLRP3 complex, suggesting a potential therapeutic role in managing gouty arthritis flares.